New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:40 EDTTKPPY, NVO, ARMHBarclays to hold a conference
European Select Conference to be held in San Francisco on June 19.
News For ARMH;NVO;TKPPY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
06:39 EDTARMHARM Holdings management to meet with Topeka
Meeting to be held in Los Angeles on March 6 hosted by Topeka.
March 3, 2015
19:02 EDTARMHARM Holdings and Tencent Games announce strategic partnership
ARM and Tencent Games announced a strategic partnership aimed at enriching mobile gamers’ graphic experiences. Through this partnership, Tencent mobile game developers will gain access to a wide range of leading-edge hardware, tools and expertise.
March 2, 2015
08:53 EDTNVONon-profit gives lukewarm review to MannKind inhaled insulin, TheStreet says
Subscribe for More Information
February 26, 2015
18:44 EDTNVONovo Nordisk receives Health Canada approval for Saxenda
Subscribe for More Information
06:30 EDTARMHARM Holdings looking to expand to Internet of Things, servers, WSJ reports
ARM Holdings (ARMH) is trying to break into the nascent Internet of Things market and the server segment, according to The Wall Street Journal. In the server market, ARM is looking to take share from Intel (INTC), the newspaper stated. Reference Link
February 20, 2015
12:02 EDTNVOEmisphere says Novo Nordisk completes Phase 2 OG217SC trial
Emisphere Technologies (EMIS) highlighted positive Phase 2 data from Eligen licensee Novo Nordisk (NVO) pertaining to OG217SC, the oral formulation of semaglutide, a long-acting human GLP-1 analogue that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. OG217SC is provided in a tablet formulation with an absorption-enhancing excipient, SNAC. SNAC is included in the Eligen Carrier Concept. Novo Nordisk announced that it has successfully completed the phase 2 trial for OG217SC, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks. Results of the study are available on Novo Nordisk's website. Based on these results, Novo Nordisk announced that it will initiate consultations with regulatory authorities subsequent to which a decision of whether to progress OG217SC into phase 3 development will be made. Under its GLP-1 License Agreement, Novo Nordisk is working to develop and commercialize oral formulations of its proprietary GLP-1 receptor agonists in combination with Emisphere carriers. Under the GLP-1 License Agreement, Emisphere could receive additional contingent product development and sales milestone payments and would also be entitled to receive royalties in the event Novo Nordisk commercializes products developed under such Agreement. Under the GLP-1 License Agreement, Novo Nordisk is responsible for the development and commercialization of the products.
05:23 EDTTKPPYTechnip awarded contract for new fertilizer unit in Slovak Republic
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use